Voluntary ACC Patient Survey
The Adrenocortical Cancer
Patient Survey has been set up because many ACC survivors and their families
have requested more information on what fellow ACC survivors are experiencing.
The information you enter will be collected and shared with others taking the
survey, in order to help them better deal with this rare disease. The
information in the survey will also help inform future research efforts for ACC.
The survey is detailed and
includes questions relating to personal information like health history, but
the results will be anonymous. AT NO TIME WILL YOU BE ASKED TO PROVIDE YOUR
NAME, IDENTIFYING INFORMATION or CONTACT INFORMATION. Reports available to you and researchers
will include only summaries of the data collected and no individual surveys
will be available.
If you would like to participate
in the survey, please click here.
OSI-906 - http://www.clinicaltrials.gov
Phase 3 clinical trial with OSI-906, A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma. NOW RECRUITING PATIENTS AT TGEN, SCOTTSDALE, ARIZONA
The ATAC Research Fund supports full time adrenal cancer research, a patient clinic located at Scottsdale Healthcare and resources dedicated only to Adrenocortical Carcinoma (adrenal cancer). Also known as cancer of the adrenal cortex or ACC, this research project is in the process of translating clinical findings into more effective treatments for Adrenocortical Carcinoma patients and to ultimately discover a cure.
The ATAC Research Fund is located at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. TGen is currently leading the most comprehensive Genomics adrenal cancer study to date and the ATAC Research project is now one of the leaders in adrenal cancer research worldwide. TGen is one of the few facilities in the world that houses such a vast array of technologies and to this date has the largest biomedical super computer anywhere. Many of these technologies have never before used on ACC research and in some cases never used on any other cancer research. TGen has and will continue to discover groundbreaking technologies and hopeful new targets, producing more Adrenocortical Carcinoma (ACC) data than ever before.
In the past 40 years, little progress has been made toward finding an effective treatments for adrenal cancer, with only one drug called Mitotane (a derivative of DDT) being approved in the last 40 years, it is obvious that new drugs need to be tested. Adrenocortical Carcinoma affects only one or two people in a 1.7 million people and is often difficult to collect enough adrenal tumors to analyze, which is why the TGen study is so significant. With your support we can find new treatments for this devastating and rare form of adrenal cancer.
THANK YOU FOR YOUR SUPPORT
The intention of this web site is to give information and attention to a rare cancer. The information provided here is not intended, nor should it be construed, as a substitute for professional medical advice. Some of these documents contain copyrighted material whose use has not been specifically authorized by the copyright owners.
